TRIL.TO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Stats
Today's Volume	60 423.00
Average Volume	127 472
Market Cap	0.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-34.06
ATR14	$0 (0.00%)

TRILLIUM THERAPEUTICS INC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TRILLIUM THERAPEUTICS INC Financials

Annual	2020
Revenue:	$148 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.700

Q3	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.180

Q2	2021
Revenue:	$10 000.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.180

Q1	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.110

Financial Reports:

No articles found.

TRILLIUM THERAPEUTICS INC

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.